At the end of your 12 month trial period, you will be offered the opportunity to continue treatment with an active treatment device for a further 4 years, free of charge, including filter changes and engineering support.
Read more →No, all other health care treatments should continue during the LASER trial.
Read more →No, your usual asthma care will continue whilst you are participating in the LASER trial. You should attend your usual scheduled asthma outpatient appointments and asthma treatments should continue alongside your trial treatment.
Read more →The LASER trial is a randomised, placebo-controlled trial. This means that we will be comparing the effect of 12 months of treatment with an active treatment device with 12 months of treatment with a placebo device. We will recruit 222 patients to the trial. Half (111) will
Read more →There are no known side effects directly attributable to the Airsonett® treatment device or Temperature-controlled Laminar Airflow treatment, a non-invasive, non-pharmaceutical treatment.
Read more →Airsonett® is a CE marked medical device and is licensed within the UK for its use in the treatment of allergic asthma.
Read more →We are investigating whether a new treatment, Temperature-controlled Laminar Airflow (TLA), delivered by a machine (Airsonett®) in the patient’s bedroom can help to improve asthma control and reduce the frequency of asthma attacks and hospital admissions.
Read more →